Literature DB >> 12938126

Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases.

Hanneke W M van Laarhoven1, Mark Rijpkema, Cornelis J A Punt, Theo J Ruers, Jan C M Hendriks, Jelle O Barentsz, Arend Heerschap.   

Abstract

PURPOSE: To investigate the reproducibility of dynamic contrast-enhanced MRI (DCE-MRI) in colorectal liver metastases using a vascular normalization function (VNF) from pixels in the spleen and to compare this with a technique using an arterial input function (AIF) from pixels in the aorta.
MATERIALS AND METHODS: DCE-MRI with gadolinium-DTPA (Gd-DTPA) was performed in patients with colorectal liver metastases. The VNF and AIF were determined using an automated algorithm. The average Gd-DTPA uptake rate (k(ep)) was calculated for the metastases using a physiological pharmacokinetic model. The protocol was repeated on a second day to calculate the repeatability coefficient of the measurements of k(ep).
RESULTS: Using the VNF from the spleen the overall mean k(ep) of the two sessions for 11 patients was 0.033 per second and the repeatability coefficient was 0.009 per second. Using the AIF from the aorta these values were 0.031 per second and 0.028 per second, respectively.
CONCLUSION: The mean Gd-DTPA uptake rate using a VNF taken from the spleen can be determined with adequate reproducibility in colorectal liver metastases. The use of a VNF from pixels in the spleen is better than an AIF from pixels in the aorta in terms of reproducibility, and is recommended when this DCE-MRI technique is used for prediction and monitoring of therapy outcome in colorectal liver metastases. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938126     DOI: 10.1002/jmri.10370

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  7 in total

1.  Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer.

Authors:  Stephanie L Barnes; Jennifer G Whisenant; Mary E Loveless; Gregory D Ayers; Thomas E Yankeelov
Journal:  Magn Reson Med       Date:  2012-07-27       Impact factor: 4.668

2.  Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation.

Authors:  Linda Heijmen; Edwin E G W Ter Voert; Iris D Nagtegaal; Paul Span; Johan Bussink; Cornelis J A Punt; Johannes H W de Wilt; Fred C G J Sweep; Arend Heerschap; Hanneke W M van Laarhoven
Journal:  Eur Radiol       Date:  2012-09-23       Impact factor: 5.315

3.  Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma.

Authors:  Bang-Bin Chen; Chao-Yu Hsu; Chih-Wei Yu; Po-Chin Liang; Chiun Hsu; Chih-Hung Hsu; Ann-Lii Cheng; Tiffany Ting-Fang Shih
Journal:  Eur Radiol       Date:  2016-12-12       Impact factor: 5.315

4.  Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.

Authors:  Linda Heijmen; Lioe-Fee de Geus-Oei; Johannes H W de Wilt; Dimitris Visvikis; Mathieu Hatt; Eric P Visser; Johan Bussink; Cornelis J A Punt; Wim J G Oyen; Hanneke W M van Laarhoven
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-04       Impact factor: 9.236

Review 5.  New approaches for precise response evaluation in hepatocellular carcinoma.

Authors:  Koichi Hayano; Jorge M Fuentes-Orrego; Dushyant V Sahani
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

6.  Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases.

Authors:  C R Chalmers; D J Wilson; J Ward; P J Robinson; G J Toogood; M A Hull
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

7.  Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.

Authors:  I M E Desar; E G W ter Voert; Th Hambrock; J J A van Asten; D J van Spronsen; P F A Mulders; A Heerschap; W T A van der Graaf; H W M van Laarhoven; C M L van Herpen
Journal:  Cancer Imaging       Date:  2012-01-12       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.